SUDA Releases Half Yearly Report; Acquisition of Subsidiary Company, Suda Europe Ltd Established & New Patent

26th February 2016, ASX Announcement

SUDA Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4D for the consolidated Group for the half year ended 31 December 2015.

Key events during the reporting period included:

i. The acquisition of the 20% minority interest in SUDA’s subsidiary company Malaria Research Company Pty Ltd;

ii. A new subsidary company, Suda Europe Ltd was established in the UK;

iii. The 2013 convertible notes which matured on 30 September 2015 were either extended by noteholders or redeemed and replaced by new noteholders;

iv. A new patent granted ArTiMist™ in Africa and the Company’s first patent allowed for SUD-003 in the USA;

v. Expanded its territorial rights to ZolpiMist®; and

vi. Business development activities have progressed across the pipeline of projects.

To read the full announcement, please click here.